期刊
NATURE IMMUNOLOGY
卷 15, 期 4, 页码 319-322出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ni.2844
关键词
-
类别
资金
- Medical Research Council UK
- National Institute of Allergy and Infectious Diseases of the US National Institutes of Health
- Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery [UM1 AI 00645]
- International AIDS Vaccine Initiative (including the US Agency for International Development and the Bill & Melinda Gates Foundation)
- Medical Research Council [MR/K012037/1] Funding Source: researchfish
- MRC [MR/K012037/1] Funding Source: UKRI
The search for a vaccine against human immunodeficiency virus type 1 (HIV-1) has many hurdles to overcome. Ideally, the stimulation of both broadly neutralizing antibodies and cell-mediated immune responses remains the best option, but no candidate in clinical trials at present has elicited such antibodies, and efficacy trials have not demonstrated any benefit for vaccines designed to stimulate immune responses of CD8(+) T cells. Findings obtained with the simian immunodeficiency virus (SIV) monkey model have provided new evidence that stimulating effective CD8(+) T cell immunity could provide protection, and in this Perspective we explore the path forward for optimizing such responses in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据